Terry Arnold is participating in the Translational Science 2022 Scientific Program in Chicago this week. She will be participating in the prestention with Duke University called Rare2Care: Community Engaged Research Model to Address Rare Cancer Health Disparities.
Our multidisciplinary team, with expertise in basic, translational and clinical research, population health and community medicine, will present a proof of concept model for utilizing community engagement strategies to address rare cancer disparities. Patients with rare cancers and their families face unique strife related to incorrect and often late diagnosis, difficulty accessing clinical skill and proper treatments, lack of confidence in clinical decision making, possible indifference in developing new drugs, and shortage of accessible cancer registries and tissue banks. These challenges can be further exacerbated if the cancer is more prevalent in a specific minority or underserved community leading to significant health disparity and poor clinical outcomes.
Leadership representing an academic medical center, a historically black college or university and a patient advocacy organization, Duke Cancer Institute, Duke Family Medicine and Community Health, North Carolina Central University and The IBC Network Foundation, will share our collective experience building a multi phase, multi pronged research consortium addressing Inflammatory Breast Cancer, IBC, a NIH designated rare disease and cancer health disparity as a model for academic community partnership to alleviate health disparities. In this session, the speakers will present strategies to a. engage primary care providers in our local and statewide communities with a large academic medical center b. improve primary care provider rare cancer knowledge and practice c. connect patients with rare cancer resources and advocacy opportunities and d. promote and entice novel research focused on both the clinical care and health equity aspects of a rare disease.
We want to thank ACTS: Association for Clinical and Translational Science for allowing us to present at the conference and Duke University for asking Terry Arnold to participate in the presentation.